ArticleThe world journal of men's health2026
Real-World Outcomes and Safety of Testosterone Therapy: A Longitudinal, Retrospective Cohort Study of Over 9,000 Men.
Article in The world journal of men's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTrials of testosterone therapy (TTh) focus on transdermal or intramuscular preparations. In clinical practice, a range of administrations are utilised, often with adjunct therapies, but evidence is limited. This study characterised the safety and effectiveness of TTh over 12 months in a real-world setting. MATERIALS AND
methodsA retrospective cohort study of adults treated by a men's health provider in the United Kingdom for testosterone deficiency between 2019 and 2024. Mixed effects models and Kaplan-Meier methodology were used. Changes in total testosterone, free testosterone, haematocrit, and quality of life (QoL; Likert scales of 1-5) domains over 12 months were evaluated overall and by baseline testosterone-defined groups.
resultsThe cohort comprised 9,537 men (median age 42 years). Mean follow-up was 8.47 months. 8,517 were treated with sub-cutaneous testosterone injections (89.20%), 366 were prescribed transdermal testosterone (3.84%), 7,079 were prescribed human chorionic gonadotropin (75.23%), 675 (7.08%) were prescribed clomiphene citrate, and 1,308 (13.72%) were prescribed tadalafil (men may have received >1 treatment). Significant increases were observed in all 8 QoL domains,
conclusionsTTh in a 'real-world setting' had a favourable safety profile and was associated with significant increases in men's sexual function, energy levels, life enjoyment, and performance in both work and sport. Future studies should support development of nuanced algorithms considering age, symptom severity and testosterone profiles to identify men likely to benefit from TTh.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.